Aktienanalyse zu Amphastar Pharmaceuticals, Inc. (AMPH)AMPHAmphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amphastar Pharmaceuticals is not a good buy right now due to declining revenue growth and negative analyst sentiment. The current price is $22.01, and the stock has a high RSI of 71.541, indicating it may be overbought. Furthermore, insiders are selling shares at an alarming rate of 4073.82%, which raises concerns about the company's future performance. The main risk is the recent FDA warning letter, which could impact product quality and sales.

6 analysts cover AMPH: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 32.00.